2019年10月12日(土) 08:40 〜 10:20 第15会場 (パレスルームB)

Organizer / Chair: Norio OZAKI (Department of Psychiatry, Nagoya University Graduate School of Medicine, Japan), Co-chair: Makoto ARAI (Tokyo Metropolitan Institute of Medical Science, Japan), Discussant: ‌Tomiki SUMIYOSHI (National Center of Neurology and Psychiatry, Japan)

Early detection and new intervention are vital in psychiatric disorders. In this symposium, four speakers will discuss the recent findings of early detection and new intervention in psychiatric disorders, ranging from rare diseases, schizophrenia, to dementia. Dr. Norio Ozaki (Nagoya University, Japan) will discuss the recent findings on elucidation of pathogenesis and developement of treatment from rare susceptilibity variants of neurodeveopmental disorders such as schizophrenia and autism spectrum disorder. Dr. Yong-Chul Chung (Chonbuk National University, Korea) will review literatures on rumination in relation to psychosis and depression and its mediating role in the development of diverse psychiatric symptoms. In addition, results on the correlations between rumination and other psychiatric symptoms measured at baseline in patients with first episode psychosis (n=440), changes of rumination score at 6 and 12 ms, and its predicting role for outcome will be presented. Based on these findings, a new perspective on the efficacy of antipsychotics on rumination will be suggested.
Dr. Hsien-Yuan Lane (China Medical University, Taiwan) will report some novel N-methyl-D-aspartate receptor (NMDAR)-related biomarkers and enhancers for diagnosis and treatment of schizophrenia in this symposium. Glutamatergic system plays a key role in pathophysiology of a number of neuropsychiatric disorders including psychiatric disorders and neurodegenerative disorders. Therefore, glutamatergic system would be the novel target for these disorders. NMDAR dysfunction plays vital roles in pathogenesis of schizophrenia. However, there have been lack of suitable biomarkers and enhancers for schizophrenia. Dr. Chieh-Hsin Lin (Kaohsiung Chang Gung Memorial Hospital, Taiwan) will talk about the clinical efficacy and safety of a D-amino acid oxidase (DAAO) in the treatment of early-phase dementia. NMDAR hypofunction is found in early-phase dementia. Current treatments for dementia are unsatisfactory. Further, feasible biomarkers for detecting dementia are also lacking. DAAO inhibitor may enhance the NMDAR neurotransmission. She also found that the peripheral DAAO levels may increase with age-related cognitive decline. The findings will help to develop novel detection and intervention at early phase of dementia.
Dr. Tomiki Sumiyoshi (National Center of Neurology and Psychiatry, Japan) will conclude the session by summarizing the information presented by the speakers, and providing an insight into the development of effective ways to intervene into the early and prodromal stages of these psychiatric conditions.